If you are referring to slide 6, I think the point was
- ACL have FDA priority
- first to file and in over 2 yrs ago
- OTHERS have to deal with long approval times, hence a positive for ACL - that's why the heading was "High barriers to entry for generic"
Your thread heading is misleading.
not good - alchemia admits fda approval delay, page-3
-
- There are more pages in this discussion • 30 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable